- Home
- Solutions
- By Services
- Therapeutics Development Services
- Therapeutic Peptide Development Service
In ophthalmology, novel and sophisticated therapeutic peptides are making strides in managing several eye diseases. Protheragen is actively involved in the development of therapeutic peptides targeting ophthalmic disorders. Given our extensive capabilities, exceptional experience, and creativity, we are positioned as a premier provider in the development of new-class ophthalmic therapeutics.
A class of biomedical molecules having great potential owing to their unique biological characteristics are therapeutic peptides. They are short, engineered amino acid chains designed to bind to certain biological elements of interest with great specificity and efficacy. Natural and synthetic origin using modern biotechnological methods, these peptides are applicable in multiple therapeutical domains such as oncology, metabolic, and infectious diseases. The biological precision of therapeutic peptides marks them as central players in contemporary medicine and drug development.
Fig.1 Different routes for ocular drug delivery. (Ahmed S., et al., 2023)The development of therapeutic peptides is a rapidly advancing multifactorial process. To achieve specific improvements in stability, bioavailability, and efficacy, researchers are utilizing advanced technologies in peptide design. As an example, novel delivery systems ensure accurate and controlled sustained release while PEGylation and cyclization improve the pharmacokinetic properties of the resulting peptides.
Table 1. Summary of therapeutic peptide for ophthalmic diseases.
| Therapeutics | Indications | Mechanism | Stage |
| RGN-259 (Thymosin beta 4) | Dry Eye Disease, Corneal Wounds, Neurotrophic Keratopathy | Promotes cell migration, reduces inflammation, and enhances corneal healing. | Phase III |
| Oxytocin | Dry Eye Disease | Stimulates tear secretion by acting on lacrimal gland receptors. May also have anti-inflammatory effects. | Phase II/III |
| ALG-1001 (Luminate) | Wet Age-related Macular Degeneration (wAMD) | An integrin-binding peptide that inhibits angiogenesis (new blood vessel formation) by blocking the interaction between integrins and extracellular matrix proteins. | Phase II |
| BRM4212 | Dry Eye Disease | Activates the Wnt/β-catenin signaling pathway, promoting cell proliferation and differentiation in the conjunctiva and cornea, potentially improving tear film stability. | Phase II |
| GS-101 (Elamipretide) | Geographic Atrophy (a form of advanced dry AMD) | Targets mitochondrial dysfunction, aiming to improve cellular energy production and reduce oxidative stress in retinal cells. | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
With Protheragen's client-centered services, clients receive support from the initial peptide design stage all the way to the preclinical and clinical phases of development. We integrate our knowledge of peptide chemistry and pharmacology with delivery systems to provide novel ocular drug development solutions.
Peptide Design and Synthesis
With the help of advanced computational tools and databases of peptide structures, we design peptides that optimize binding affinity and specificity. We guarantee consistency and purity in every synthesized batch, covering a wide range of lengths and complexities of peptides.
Modifications and Optimization
We provide several peptide modifications to increase their stability and effectiveness. Some of these are PEGylation for increased half-life, cyclization for improved proteolysis resistance, and conjugation to tissue-specific targeting ligands.
In Vitro and In Vivo Testing
Binding, receptor activation, and cytotoxicity assessments of peptides are done via in vitro assays. Relevant animal model studies provide data regarding the efficacy, safety, and biodistribution of the peptides, assisting us in determining which peptides warrant further examination and development.
Formulation Development
Our company specializes in the creation of novel formulations intended to enhance the delivery of therapeutic peptides to the eye. We have sustained release formulations, bioactive nanoparticles, and hydrogels that improve peptide's bioavailability and duration of action.
At Protheragen, we understand that each client has unique requirements. Our customized services are designed to meet these specific needs, offering tailored solutions for peptide development. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.